The bill HB2489, also known as the "PTSD Treatment Act of 2023," aims to recognize any compound, mixture, or preparation containing 3, 4-methylenedioxymethamphetamine (MDMA) as a controlled substance in Arizona, provided it is approved by the U.S. Food and Drug Administration (FDA) and rescheduled by the U.S. Drug Enforcement Administration (DEA) to a schedule other than Schedule I. This would allow such substances to be prescribed in Arizona.

The bill amends sections 36-2511 and adds section 36-2517.01 to the Arizona Revised Statutes, relating to controlled substances. It specifies that upon federal approval and rescheduling, MDMA-containing products can be prescribed, reflecting the Legislature's intent to provide rapid access to this treatment option for conditions such as PTSD. The bill's effectiveness is contingent on the approval of an MDMA product by January 1, 2026, and requires the Director of the Arizona State Board of Pharmacy to notify the Director of Legislative Council of the approval status by February 1, 2026.

Statutes affected:
Introduced Version: 28-1326
House Engrossed Version: 36-2511, 36-2517.01, 36-2512, 36-2513, 36-2514, 36-2515, 36-2516, 36-2517
Chaptered Version: 36-2511, 36-2517.01, 36-2512, 36-2513, 36-2514, 36-2515, 36-2516, 36-2517